Amgen Inc. can move forward with its $27.8 billion takeover of Horizon Therapeutics Plc after the U.S. Federal Trade Commission said that it accepted a binding settlement that the combined company won’t bundle together two of Horizon’s blockbuster drugs.
To read the entire story, you must be logged in.
Please log in now or register with us.
